
Vitrolife Update - Modest stable growth with great margins

Vitrolife delivered a consecutive positive organic growth recovery with 6% organic growth in constant currencies (CER). The last three quarters are near market growth. The extra 4-5% growth needed to reach its target of >10% will take longer, considering that some 3% of Vitrolife's business will fade out to comply with sanctions and international policies during 2025.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Vitrolife Update - Modest stable growth with great margins](#)